Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Docetaxel and ZD1839 in High Risk Prostate Cancer
NCT00242918Phase 2Completed
- Sponsor
- Benaroya Research Institute
- Start
- May 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and gefitinib in prostate cancer (PCa), sponsored by Benaroya Research Institute. Primary endpoint: Pathologic Complete Response. Started May 2003; status: completed.
02
Drugs
docetaxelgefitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00242918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242918.